Sandoz

(IN BRIEF) SGS announced that Chair of the Board of Directors Calvin Grieder will step down at the company’s Annual General Meeting on March 26, 2026. Grieder, who has served on the Board since 2019 and as Chair since 2020, … Read the full press release →

(IN BRIEF) Sandoz has launched Afqlir®, its biosimilar to aflibercept, across Europe following European Commission approval in 2024. Equivalent in efficacy, safety, and pharmacokinetics to Eylea®, Afqlir® provides a lower-cost treatment option for serious retinal diseases such as nAMD, RVO, … Read the full press release →

(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease. Developed by Polpharma Biologics, TYRUKO® is clinically equivalent to its reference product and … Read the full press release →

(IN BRIEF) Sandoz has signed a 10-year virtual PPA with Elawan Energy to develop 150 MW of new solar capacity in Valladolid, Spain, expected to meet almost 90% of electricity demand for its European operations. This partnership is a key … Read the full press release →

(IN BRIEF) Novartis has appointed Mukul Mehta as CFO and Executive Committee member effective March 16, 2026. He will replace long‑time CFO Harry Kirsch, who retires on March 15, 2026, after 22 years at the company. Kirsch oversaw major strategic … Read the full press release →

(IN BRIEF) Sandoz has announced the retirement of Francisco Ballester, President of Region International, after 34 years of service, effective March 1, 2025. Francisco has been instrumental in expanding business growth and patient access in markets outside North America and … Read the full press release →